Radiopharmaceutical therapy (RPT) is a rapidly advancing field that uses radioactive materials for cancer treatment. Unlike conventional radiotherapy, RPT uses radiation in a systemic way, which means that the radiation-emitting particles are delivered through the bloodstream and can target cancer cells throughout the body. RPT is highly effective in treating several types of cancers, including neuroendocrine tumors or metastatic prostate cancer. However, RPT has several challenges that limit its effectiveness. Patients might be underdosed leading to ineffective or suboptimal treatment due to the current administration schedules, including a fixed activity per cycle for everyone. To address this issue, there is a need for innovative approaches to dosimetry and radiation biology experiments and modeling.
The goal of this Research Topic is to explore innovative approaches to alpha-particle radiopharmaceutical therapy (RPT) dosimetry and radiation biology experiments and modeling. Alpha particles are highly effective in killing cancer cells due to their high linear energy transfer (LET) and relative biological effectiveness (RBE). However, specific radiation biology studies are necessary for dosimetry in alpha particle-RPT as their effects are different from conventional radiation or beta emitters. Moreover, dosimetry methods are underdeveloped in RPT, which limits the effectiveness of RPT. Also, alpha-RPT has specific problems such as the low photon yield due to low administered activities, which makes SPECT-based dosimetry impractical yet. Recent advances in dosimetry methods, computational modeling, and experimental studies have provided new opportunities to develop better approaches for alpha-particle RPT dosimetry and radiation biology experiments. In this Research Topic, we aim to address the challenges and explore innovative solutions that could enhance the effectiveness of RPT.
This Research Topic invites contributions that explore innovative approaches to alpha-particle radiopharmaceutical therapy dosimetry and radiation biology experiments and modeling. We welcome Original Research, \review articles, and Methods papers that cover a broad range of topics, including but not limited to:
- New methods for macroscopic and microscopic dosimetry
- Experimental studies investigating the effects of alpha particles on cancer cells
- Computational modeling at multiple scales, from the cellular to the organ level
- Theoretical and experimental work on the interaction between alpha particles and biological systems
- Studies on radiobiological effects of alpha-particle RPT compared to conventional radiation or beta emitters
- Investigations showing the dose-response of new alpha-emitting radiopharmaceuticals
- Reviews of current status and future directions in alpha-particle RPT
We encourage authors to submit their original work, which will undergo rigorous peer-review. The Research Topic aims to provide a comprehensive overview of the state-of-the-art in alpha- particle RPT dosimetry and radiation biology experiments and modeling.
Keywords:
Alpha therapy, Dosimetry, Radiopharmaceuticals
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
Radiopharmaceutical therapy (RPT) is a rapidly advancing field that uses radioactive materials for cancer treatment. Unlike conventional radiotherapy, RPT uses radiation in a systemic way, which means that the radiation-emitting particles are delivered through the bloodstream and can target cancer cells throughout the body. RPT is highly effective in treating several types of cancers, including neuroendocrine tumors or metastatic prostate cancer. However, RPT has several challenges that limit its effectiveness. Patients might be underdosed leading to ineffective or suboptimal treatment due to the current administration schedules, including a fixed activity per cycle for everyone. To address this issue, there is a need for innovative approaches to dosimetry and radiation biology experiments and modeling.
The goal of this Research Topic is to explore innovative approaches to alpha-particle radiopharmaceutical therapy (RPT) dosimetry and radiation biology experiments and modeling. Alpha particles are highly effective in killing cancer cells due to their high linear energy transfer (LET) and relative biological effectiveness (RBE). However, specific radiation biology studies are necessary for dosimetry in alpha particle-RPT as their effects are different from conventional radiation or beta emitters. Moreover, dosimetry methods are underdeveloped in RPT, which limits the effectiveness of RPT. Also, alpha-RPT has specific problems such as the low photon yield due to low administered activities, which makes SPECT-based dosimetry impractical yet. Recent advances in dosimetry methods, computational modeling, and experimental studies have provided new opportunities to develop better approaches for alpha-particle RPT dosimetry and radiation biology experiments. In this Research Topic, we aim to address the challenges and explore innovative solutions that could enhance the effectiveness of RPT.
This Research Topic invites contributions that explore innovative approaches to alpha-particle radiopharmaceutical therapy dosimetry and radiation biology experiments and modeling. We welcome Original Research, \review articles, and Methods papers that cover a broad range of topics, including but not limited to:
- New methods for macroscopic and microscopic dosimetry
- Experimental studies investigating the effects of alpha particles on cancer cells
- Computational modeling at multiple scales, from the cellular to the organ level
- Theoretical and experimental work on the interaction between alpha particles and biological systems
- Studies on radiobiological effects of alpha-particle RPT compared to conventional radiation or beta emitters
- Investigations showing the dose-response of new alpha-emitting radiopharmaceuticals
- Reviews of current status and future directions in alpha-particle RPT
We encourage authors to submit their original work, which will undergo rigorous peer-review. The Research Topic aims to provide a comprehensive overview of the state-of-the-art in alpha- particle RPT dosimetry and radiation biology experiments and modeling.
Keywords:
Alpha therapy, Dosimetry, Radiopharmaceuticals
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.